Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

FLUIDDA Presents Novel Imaging Technology for Respiratory Diseases to FDA

Published: Thursday, December 19, 2013
Last Updated: Thursday, December 19, 2013
Bookmark and Share
The FDA hearing is planned for January 17th in Washington DC.

FLUIDDA develops proprietary Functional Respiratory Imaging (FRI) technology that provides a unique entry point into personalized medicine for respiratory diseases.

FRI reduces significantly the number of patients needed in clinical trials, resulting in better drugs coming to the market faster.

FLUIDDA is invited by the FDA to present the benefits of this unique technology for the screening of new respiratory drugs.

Functional Respiratory Imaging (FRI) is FLUIDDA’s proprietary imaging technology with the unique capability of producing highly clinical relevant patient specific biomarkers. These biomarkers present 3D visualization of the patient’s airway and lung geometry, airway resistance and aerosol deposition patterns.

Extensive patient studies demonstrated that FRI has enhanced sensitivity compared to the conventional tests. FRI detects changes in the respiratory system caused by a drug more accurately in fewer patients.

This allows a significant reduction in the number of patients that are needed in clinical trials for people suffering from respiratory diseases such as asthma and COPD (Chronic Obstructive Pulmonary Disease). This implies that better drugs could come to market faster.

FLUIDDA has been invited by the renowned US Food and Drug Administration (FDA) to present the study data concerning their novel biomarker for respiratory diseases. This meeting is a part of the critical path initiative by FDA to endorse the development of new biomarkers to increase the efficiency of drug development.

Jan De Backer, CEO of FLUIDDA, commented: “This invitation is very important for FLUIDDA. Positive feedback from FDA regarding FRI will be a strong signal for pharmaceutical companies to include FRI endpoints in their clinical trials.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos